Plasminogen binds to plasmin-modulated factor Xa by Ca2+- and C-terminal lysine-dependent and -independent interactions

Jean E. Grundy; Mark A. Hancock; Scott C. Meixner; Roger C. MacKenzie; Marlys L. Koschinsky; Edward L. G. Pryzdial

doi:10.1160/TH06-08-0476

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 97(01): 38-44
DOI: 10.1160/TH06-08-0476

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Plasminogen binds to plasmin-modulated factor Xa by Ca2+- and C-terminal lysine-dependent and -independent interactions

Authors

Jean E. Grundy

¹Canadian Blood Services, R&D Department, University of British Columbia/Centre for Blood Research, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
Mark A. Hancock

²Department of Biochemistry, Queen’s University, Kingston, Ontario, Canada
Scott C. Meixner

¹Canadian Blood Services, R&D Department, University of British Columbia/Centre for Blood Research, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
Roger C. MacKenzie

³Institute of Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada
Marlys L. Koschinsky

²Department of Biochemistry, Queen’s University, Kingston, Ontario, Canada
Edward L. G. Pryzdial

¹Canadian Blood Services, R&D Department, University of British Columbia/Centre for Blood Research, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada

Abstract

Summary

Plasminogen binding to receptors involves both C-terminal lysine-dependent and -independent interactions. The latter are poorly understood. Our earlier work demonstrated a novel Ca²⁺-enhanced bivalent interaction between plasmin-cleaved FXa (FXa33/13) and plasminogen truncated at Lys78 (Lys-Pg). Here we hypothesized that the effects of Ca²⁺may enable dissection of the C-terminal lysine-dependent and -independent interactions. To evaluate the role of the Glu-plasminogen (Glu-Pg) amino acids 1–77, binding of FXa33/13 to immobilized Glu-Pg was compared to Lys-Pg by surface plasmon resonance. Under identical conditions, approximately half the amount of FXa33/13 bound to Glu-Pg. The simplest fit of data suggested a 2:1 plasminogen:FXa33/13 stoichiometry for both, which were proportionately enhanced by Ca²⁺. Only Lys-Pg demonstrated significant Ca²⁺-independent binding to FXa33/13. In the presence of Ca²⁺, weak C-terminal lysine-independent binding could be detected, but only for Glu-Pg. The elastase-generated plasminogen fragment encompassing the angiostatin-like kringle domains 1 to 3 (K1–3) inhibited binding of FXa33/13 to Lys-Pg, whereas fragments corresponding to kringle 4- and kringle 5-protease domain had no effect. Immobilized K1–3 binding to FXa33/13 had both Ca²⁺-dependent and -independent components. The principal KM_d for the interaction was 10-fold higher than Lys-Pg. In the presence of Ca²⁺, eACA inhibited FXa33/13 binding to K1–3 by 30%, but eliminated binding in the absence of Ca²⁺. These studies suggest that Ca²⁺-dependent and -independent binding of Lys-Pg to FXa33/13 are C-terminal lysine-dependent. The N-terminal 1–77 amino acids of Glu-Pg confer significant C-terminal lysine-independent binding, which may play a role during the initiating stages of plasminogen activation.

Keywords

Coagulation factors - protein function / activity - plasminogen (-fragments) - Gla-domain proteins

Full Text

References

References
1 Fredenburgh JC, Nesheim ME. Lys-plasminogen is a significant intermediate in the activation of Glu-plasminogen during fibrinolysis in vitro. J Biol Chem 1992; 267: 26150-6.
2 Claeys H, Vermylen J. Physico-chemical and proenzyme properties of NH2-terminal glutamic acid and NH2-terminal lysine human plasminogen. Influence of 6-amino-hexanoic acid. Biochem Biophys Acta 1974; 342: 351-9.
3 Miles LA, Castellino FJ, Gong Y. Critical role for conversion of Glu-plasminogen to Lys-plasminogen for optimal stimulation of plasminogen activation on cell surfaces. Trends Cardiovasc Med 2003; 13: 21-30.
4 Castellino FJ, McCance SG. The kringle domains of human plasminogen. Ciba Foundation Symposium 1997; 212: 46-60.
5 Collen DH, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
6 Longstaff C, Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Letters 2005; 579: 3303-9.
7 Bass R, Ellis V. Cellular mechanisms regulating non-haemostatic plasmin generation. Biochemic Soc Trans 2002; 30: 189-94.
8 Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Brit J Haematol 2005; 129: 307-21.
9 Kwon M, MacLeod TJ, Zhang Y. et al S100A10, annexin A2 and annexin A2 heterotetramer as candidate plasminogen receptors. Frontiers Biosci 2005; 10: 300-25.
10 Felez J, Miles LA, Fabregas P. etal Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocytic cells. Thromb Haemost 1996; 76: 577-84.
11 Markus G. Conformational changes in plasminogen, their effect on activation, and the agents that modulate activation rates – a review. Fibrinolysis 1996; 10: 75-85.
12 Wistedt AC, Kotarsky H, Marti D. et al Kringle 2 mediates high affinity binding of plasminogen to an internal sequence in streptococcal surface protein PAM. J Biol Chem 1998; 273: 24420-4.
13 Chang Y, Mochalkin I, McCance SG. et al Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochem 1998; 37: 3258-71.
14 Graversen JH, Lorentsen RH, Jacobsen C.. et al The plasminogen site of the C-type lectin tetranectin is located in the carbohydrate recognition domain, and binding is sensitive to both calcium and lysine. Journal of Biological Chemistry 1998; 273: 29241-6.
15 Pryzdial ELG, Bajzar L, Nesheim ME. Prothrombinase components can accelerate tissue plasminogen activator-catalyzed plasminogen activation. J Biol Chem 1995; 270: 17871-7.
16 Pryzdial ELG, Kessler GE. Autoproteolysis or plasmin-mediated cleavage of factor Xa exposes a plasminogen binding site and inhibits coagulation. J Biol Chem 1996; 271: 16614-20.
17 Grundy JE, Lavigne N, Hirama T. et al Binding of plasminogen and tissue plasminogen activator to plasmin-modulated factor X and factor Xa. Biochem 2001; 40: 6293-302.
18 Krishnaswamy S, Nesheim ME, Pryzdial EL. et al Assembly of prothrombinase complex. Methods Enzymol 1993; 222: 260-80.
19 Wahl ML, Kenan DJ, Gonzalez-Lopez M et al. Angiostatin’s molecular mechanism: Aspects of specificity and regulation elucidated. J Cell Biochem 2005; 96: 242-61.
20 Hancock MA, Spencer CA, Koschinsky ML. Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance. Biochem 2004; 43: 12237-48.
21 Jönsson U, Fägerstam L, Ivarsson B. et al Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 1991; 11: 620-7.
22 Mackenzie CR, Hirama T, Lee KK et al. Quantitative analysis of bacterial toxin affinity and specificity for glycolipid residues by surface plasmon resonance. J Biol Chem 1997; 272: 5533-8.
23 Hajjar KA, Nachman RL. Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface. J Clin Inv 1988; 82: 1769-78.
24 Nesheim M, Fredenburgh JC, Larsen GR. The dissociation constants and stoichiometries of the interaction of Lys-plasminogen and chloromethylketone derivatives of tissue plasminogen activator and the variant delta-FEIX with intact fibrin. J Biol Chem 1990; 265: 21541-8.
25 Miles LA, Dahlberg CM, Plescia J. et al Role of cell-surface lysines in plasminogen binding to cells: Identification of alpha-enolase as a candidate plasminogen receptor. Biochem 1991; 30: 1682-91.
26 Plow EF, Felez J, Miles LA. Cellular regulation of fibrinolysis. Thromb Haemost 1991; 66: 32-6.
27 Dudani AK, Hashemi S, Aye MT. et al Identification of an endothelial cell surface protein that binds plasminogen. Mol Cell Biochem 1991; 108: 133-9.
28 Dudani AK, Cummings C, Hashemi S. et al Isolation of a novel plasminogen receptor from human endothelial cells. Thromb Res 1993; 69: 185-96.
29 Kelm Jr. RJ, Swords NA, Orfeo T. et al Osteonectin in matrix remodeling: A plasminogen-osteonectin-collagen complex. J Biol Chem 1994; 269: 30147-53.
30 Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator: identity with annexin II. J Biol Chem 1994; 269: 21191-7.
31 Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator: Annexin II-mediated enhancement of tPA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-203.
32 Kassam G, Choi KS, Ghuman J. et al The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 1998; 273: 4790-9.
33 Persson E, Hogg PJ, Stenflo J. Effects of Ca2+ binding on the protease module of factor Xa and its interaction with factor Va. Evidence for two Gla-independent Ca(2+)-binding sites in factor Xa. J Biol Chem 1994; 268: 22531-9.
34 O’Reilly MS, Holmgren L, Shing Y.. et al Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
35 Iino M, Takeya H, Takemitsu T. et al Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization of the factor Xa binding site on fibrinogen. Eur J Biochem 1995; 232: 90-7.